FOLH1 and prostate carcinoma: Radiotheranostics combining [68Ga]Ga-PSMA-11 and [177Lu]Lu-PSMA-617 have been approved and are used in USA and EU [94, 95]; radiotheranostics using prostate-specific membrane antigen (PSMA) ligands in patients with prostate cancer has attracted much attention in recent nuclear medicine (Fig. 10).